SINTX Technologies, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, as detailed in its recent 10-K filing. The company generated total revenue of $1.018 million, a decrease of 65% from $2.887 million in 2024. This decline was primarily attributed to a 41% drop in product revenue, which fell to $729,000 from $1.246 million, and an 82% decrease in grant and contract revenue, which dropped to $289,000 from $1.641 million. The company cited a strategic shift away from low-margin OEM contracts as a key factor in this revenue decline, focusing instead on proprietary silicon nitride-based biomedical devices that promise higher margins and long-term value.
In terms of operational metrics, SINTX's gross profit also saw a substantial decrease, falling 78% to $461,000 compared to $2.076 million in the previous year. The cost of revenue decreased by 31% to $557,000, reflecting the overall reduction in sales. Research and development expenses were reduced by 12% to $4.587 million, while general and administrative expenses increased by 55% to $6.197 million, largely due to higher stock-based compensation and costs associated with departing board members. The company reported a net loss of $10.364 million, a slight improvement from the $11.024 million loss in 2024.
Strategically, SINTX has made significant moves to reposition itself within the market. The company received FDA 510(k) clearance for its SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025, marking its entry into reconstructive foot and ankle surgery. This product, along with the OsseoSculpt™ biologic, is expected to drive revenue growth in 2026. Additionally, SINTX has entered into an At The Market Offering Agreement to raise up to $6.4 million, with $6 million remaining available under this program as of year-end.
Operationally, SINTX has streamlined its workforce and ceased operations at its armor plant, which had not been fully operational since its acquisition in 2021. The company is now focused on expanding its product lines in the biomedical sector, leveraging its expertise in silicon nitride technology. As of December 31, 2025, SINTX had 32 employees, reflecting a commitment to maintaining a lean operational structure while pursuing growth opportunities in high-demand medical applications.
Looking ahead, SINTX Technologies faces challenges in achieving profitability, with an accumulated deficit of $292.1 million as of year-end. The company acknowledges the need for substantial future capital to support ongoing operations and product development. While management is optimistic about the potential of its new product offerings, the path to sustainable growth remains contingent on market acceptance and the successful execution of its strategic initiatives.
About Sintx Technologies, Inc.
SINTX Technologies specializes in advanced ceramics, primarily silicon nitride, for biomedical and antipathogenic applications. Its core business includes manufacturing and developing implantable medical devices such as spinal fusion and joint replacement components, leveraging properties like biocompatibility, osteointegration, and antibacterial resistance. The company also explores antimicrobial surfaces and coatings, targeting healthcare markets worldwide with proprietary, FDA-registered manufacturing capabilities and a focus on innovation and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.